Global challenges in breast cancer detection and treatment

被引:126
作者
Barrios, Carlos H. [1 ]
机构
[1] Brazil Oncoclin Grp, Latin Amer Cooperat Oncol Grp LACOG Porto Alegre, Porto Alegre, RS, Brazil
关键词
Breast cancer detection; Breast cancer treatment; Early diagnosis; Healthcare discrepancies; Screening; Low- and middle-income countries; ADJUVANT CHEMOTHERAPY; LATIN-AMERICA; TRASTUZUMAB; COUNTRIES; SURVIVAL;
D O I
10.1016/j.breast.2022.02.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer represents an urgent global priority. While this is a universal issue, and as the burden of the disease is increasing globally, current estimates indicate that in the next couple of decades, much of the incidence and mortality related to breast cancer will be seen in underserved populations. The fragile and ill-prepared healthcare systems in low- and middle-income countries (LMIC) need to address this challenge and find solutions with their limited resources. Significant disparities can be identified in stage at presentation as the ability to detect the disease in earlier stages is compromised in these scenarios leading to worse outcomes associated to late diagnoses. Furthermore, access to healthcare in general and to basic surgical, radiotherapy and systemic care is suboptimal additionally limiting treatment results. With a small portion of their budget allocated to healthcare, LMIC need to make the most of their resources prioritizing cost-effective strategies that could offer the best possible results. Countries that invest in women's health do develop into healthier, more educated, and importantly, more productive societies with benefits seen across generations. Finally, recognition of inequities should stimulate a concerted effort engaging all involved stakeholders to find context-adapted solutions to improve healthcare outcomes.
引用
收藏
页码:S3 / S6
页数:4
相关论文
共 29 条
[1]   Breast Cancer-Thinking Globally [J].
Anderson, Benjamin O. .
SCIENCE, 2014, 343 (6178) :1403-1403
[2]  
[Anonymous], 2020, CANCERDISPARITIESPRO
[3]  
[Anonymous], 2019, WHO TECHN REP SER, V1021
[4]  
[Anonymous], 2017, Guide to cancer early diagnosis
[5]  
[Anonymous], 2020, WHO REP CANC SETT PR
[6]  
Barrios CH, 2021, LANCET ONCOL, V22, pE474, DOI 10.1016/S1470-2045(21)00492-7
[7]  
Barrios CH, JCO GLOBAL ONCOL, V7, P474
[8]   11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].
Cameron, David ;
Piccart-Gebhart, Martine J. ;
Gelber, Richard D. ;
Procter, Marion ;
Goldhirsch, Aron ;
de Azambuja, Evandro ;
Castro, Gilberto, Jr. ;
Untch, Michael ;
Smith, Ian ;
Gianni, Luca ;
Baselga, Jose ;
Al-Sakaff, Nedal ;
Lauer, Sabine ;
McFadden, Eleanor ;
Leyland-Jones, Brian ;
Bell, Richard ;
Dowsett, Mitch ;
Jackisch, Christian .
LANCET, 2017, 389 (10075) :1195-1205
[9]   Trends and predictions to 2020 in breast cancer mortality in Europe [J].
Carioli, Greta ;
Malvezzi, Matteo ;
Rodriguez, Teresa ;
Bertuccio, Paola ;
Negri, Eva ;
La Vecchia, Carlo .
BREAST, 2017, 36 :89-95
[10]   Enhancing global access to cancer medicines [J].
Cortes, Javier ;
Perez-Garcia, Jose Manuel ;
Llombart-Cussac, Antonio ;
Curigliano, Giuseppe ;
El Saghir, Nagi S. ;
Cardoso, Fatima ;
Barrios, Carlos H. ;
Wagle, Shama ;
Roman, Javier ;
Harbeck, Nadia ;
Eniu, Alexandru ;
Kaufman, Peter A. ;
Tabernero, Josep ;
Garcia-Estevez, Laura ;
Schmid, Peter ;
Arribas, Joaquin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (02) :105-124